

## Anti-LIV-1/SLC39A6 Antibody ((ladiratuzumab vedotin)

### Introduction

Ladiratuzumab vedotin (SGN-LIV1A, anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) consisting of a humanized anti-LIV-1 antibody conjugated to Monomethyl auristatin E (MMAE) via a proteolytically cleavable linker. Ladiratuzumab vedotin has the potential to be used in a variety of cancers.

### Product parameters

Alternative Names	SGN-LIV1A, MK-6440
Target Accession	Q13433
Target	LIV-1 / SLC39A6
CAS number	1629760-29-7
Molecular Weight	146.96 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human LIV 1, His Tag at 2 ug/mL can bind Anti-LIV-1 / SLC39A6 Reference Antibody (Ladiratuzumab vedotin), EC50 is 0.007652 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

